SPC258
Eravasýklín eða lyfjafræðilega viðunandi salt þar af
Status:
VeittApplication date:
18.3.2019Application published:
15.4.2019Grant published:
15.8.2020
Max expiry date:
23.9.2033Medicine name:
XeravaMedicine for children:
No
Timeline
Today
18.3.2019Application
15.4.2019Publication
15.8.2020Registration
23.9.2033Expires
Marketing license
IS authorization number:
EU/1/18/1312/001Date:
24.10.2018
Foreign authorization number:
EU/1/18/1312Date:
20.9.2018
Owner
Name:
Tetraphase Pharmaceuticals, Inc.Address:
480 Arsenal Street, Suite 110, Watertown US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105 Reykjavík
Patent
Number:
EP2323972